Intended for healthcare professionals

Letters Strategy to promote inclisiran

We still don’t know whether inclisiran protects patients

BMJ 2024; 384 doi: https://doi.org/10.1136/bmj.q369 (Published 22 February 2024) Cite this as: BMJ 2024;384:q369
  1. Bob Michell, emeritus professor of biochemistry
  1. University of Birmingham, Birmingham, UK
  1. r.h.michell{at}bham.ac.uk

The UK government’s new policy to fast track “innovative” drugs into the NHS has been called a “spectacular failure” because of how a test case using the cholesterol lowering drug inclisiran was received.1

In January 2020, I sent The BMJ a response saying that it was at that …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription